Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153

斯迪富维持Glaukos(GKOS.US)买入评级，上调目标价至153美元

moomoo资讯 · 12/02 20:31 · 评级/大行评级

Stifel analyst Thomas Stephan maintains $Glaukos (GKOS.US)$ with a buy rating, and adjusts the target price from $145 to $153.

According to TipRanks data, the analyst has a success rate of 46.7% and a total average return of 10.8% over the past year.

AnalystRecentRatingAutoNews_211107_20241202_12eeb75d1481aa640459fc05618c25d4d0b1b531_1733218320888411_mm_en

Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:

iDose is recognized as an excellent product with significant long-term potential. However, the current valuation poses challenges in identifying further upside relative to other stocks. Additionally, while there are promising assets in development, their realization is expected to take some time.
Recent tracking indicates a resurgence in the number of new iDose-trained surgeons, bolstering confidence in surpassing the predicted $100M iDose sales by 2025. Continued advancements in Medicare Administrative Contractor reimbursements are also foreseen to significantly accelerate iDose revenue growth by mid-2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

斯迪富分析师Thomas Stephan维持$Glaukos (GKOS.US)$买入评级，并将目标价从145美元上调至153美元。

根据TipRanks数据显示，该分析师近一年总胜率为46.7%，总平均回报率为10.8%。

AnalystRecentRatingAutoNews_211107_20241202_12eeb75d1481aa640459fc05618c25d4d0b1b531_1733218320888411_mm_sc

此外，综合报道，$Glaukos (GKOS.US)$近期主要分析师观点如下：

iDose被公认为具有巨大长期潜力的优秀产品。但是，当前的估值在确定相对于其他股票的进一步上行空间方面构成了挑战。此外，尽管有前景的资产正在开发中，但其实现预计需要一些时间。
最近的追踪表明，接受过iDose培训的新外科医生人数有所回升，这增强了人们对到2025年超过预期的1亿美元iDose销售额的信心。预计到2025年中期，医疗保险管理承包商报销的持续进展将显著加速iDose收入的增长。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153

Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153

风险及免责提示

声明